trial · primary record
oxaliplatin
Biliary Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2042-06-01 |
| Primary endpoint | Phase I: Safe dose of CDX-1140 in combination with CAPOX and Keytruda(R) |
| Registry ID | NCT05849480 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:45.038Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05849480
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.